French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for a 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.
https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersSanofi6-29-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-29 09:01:322022-06-29 12:39:20Sanofi caps out-of-pocket insulin cost at $35 for uninsured U.S. patients
